← 홈

Antibody

163개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 163개
AntibodystaleBristol-Myers SquibbPhase 2

Lirilumab (Lirilumab)

Non-Hodgkin's Lymphoma; Hodgkin Lymphoma · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase2#항체#면역항체+4
효능 ORR 66.7%임상시험 13상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab and Talazoparib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 0%임상시험 8상태 RECRUITING
AntibodystaleInnoventPhase 2

Sintilimab+Pegaspargase (Sintilimab+Pegaspargase)

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Natural Killer/T-Cell Lymphoma, Nasal an

#NaturalKillerT-CellLymphomaNasal#Antibody#Phase2#항체#면역항체+5
임상시험 8상태 RECRUITING
AntibodystaleKite, A Gilead CompanyPhase 1

Lenzilumab (Lenzilumab)

Relapsed/Refractory Large B-cell Lymphoma · FRα

#FR#Antibody#Phase1#항체#면역항체+4
효능 ORR 9.9%임상시험 6상태 DISCONTINUED
AntibodystaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 4상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab [TECENTRIQ])

Neoplasms · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 33.33%임상시험 4상태 ACTIVE
AntibodystaleHoffmann-La RochePhase 2

Rituxumab (Rituxumab)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 95%임상시험 4상태 ACTIVE
AntibodyBiologicstaleGenentech, Inc.Phase 2

Bispecific antibody-based combined with CAR-T cell therapy (Bispecific antibody-based combined with CAR-T cell therapy)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 3상태 RECRUITING
AntibodystaleAmgenPhase 2

MT103 (Blinatumomab, Blinatumomab (MT103))

Non-Hodgkin's Lymphoma, Relapsed · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Phase2#항체#면역항체+4
효능 ORR 11.1%임상시험 2상태 ACTIVE
AntibodystaleRochePreclinical

CHOP+RITUXIMAB (CHOP+RITUXIMAB)

Non-Hodgkins Lymphoma · Lymphoma, Large-Cell, Diffuse

#LymphomaLarge-CellDiffuse#Antibody#Preclinical#항체#면역항체+3
임상시험 2상태 ACTIVE
AntibodystaleRochePhase 2

Rituximab/Gemcitabine/Oxaliplatin (Rituximab/Gemcitabine/Oxaliplatin)

Refractory Aggressive Non-Hodgkin's Lymphoma; Relapsing Aggressive Non-Hodgkin's Lymphoma · Combination Therapy

#CombinationTherapy#Antibody#Phase2#항체#면역항체+4
효능 ORR 69.7%임상시험 2상태 RECRUITING
AntibodystalePETHEMA FoundationPhase 2

ibritumomab tiuxetan (ibritumomab tiuxetan)

Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
효능 ORR 89%임상시험 2상태 DISCONTINUED
AntibodystaleMaisonneuve-Rosemont HospitalPhase 2

Zevalin (90Y ibritumomab tiuxetan, 90Y ibritumomab tiuxetan (Zevalin))

Non-Hodgkins Lymphoma · Non-Hodgkins Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodySun Yat-sen UniversityPhase 2

Adebrelimab & SHR2554 (Adebrelimab & SHR2554)

Relapsed or Refractory Peripheral T Cell Lymphoma; NKTCL · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleGoethe UniversityPhase 2

MabCampath (Alemtuzumab, Alemtuzumab (MabCampath))

Adult Acute Lymphocytic Leukemia T-cell; Lymphoma, Lymphoblastic · Adult Acute Lymphocytic Leukemia T-cell

#AdultAcuteLymphocyticLeukemiaT-c#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleGlaxoSmithKlinePhase 2

Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody, Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab))

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ])

Lymphoma, Follicular · Lymphoma, Follicular

#LymphomaFollicular#Antibody#Phase2#항체#면역항체+4
효능 ORR 87.5%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 1

bendamustine, rituximab, ibrutinib (BR-I, BR-I (bendamustine, rituximab, ibrutinib))

Mantle Cell Lymphoma; Lymphoma · Mantle Cell Lymphoma

#MantleCellLymphoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleInternational Extranodal Lympho…Phase 2

Bendamustine and Rituximab (Bendamustine and Rituximab)

Marginal Zone B-cell Lymphoma · Marginal Zone B-cell Lymphoma

#MarginalZoneB-cellLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 91%임상시험 1상태 ACTIVE
AntibodystaleGenzyme, a Sanofi CompanyPhase 2

alemtuzumab (CAMPATH, CAMPATH (alemtuzumab))

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED

3 / 9 페이지

← 이전다음 →